Coronary artery disease (CAD) is the most prominent cause of death worldwide and contributes extensively to the economic burden of health care costs. To date, numerous cardiovascular imaging modalities designed to assess CAD have been introduced for clinical performance. Among those, much focus has been placed on computed tomography (CT)-based methods that include: coronary artery calcium (CAC) score, coronary CT angiography (CCTA), myocardial CT perfusion (CTP), fractional flow reserve derived from CT (FFR CT ). The current review provides an overview regarding the benefits, limitations, and future directions of CT and discusses the appropriate use of CT in detecting CAD.
Introduction
of CAC for incident stroke. 5) In the 2013 American College of Cardiology/American Heart Association guidelines, CAC was given a class IIb recommendation for assessment of cardiovascular risk in asymptomatic adults. 6 ) CAC ≥ 300 may be taken into consideration, similar to family history, among patients with a 5-7.5% 10-year estimated risk of atherosclerotic cardiovascular disease using the newly developed pooled cohort equations. Although CAC score may reflect a strong tool for early detection of coronary atherosclerosis, several limitations should be considered. First, CAC is extremely limited when identifying the non-calcified plaque components of CAD. 7) Thus, while the quantification of coronary calcium strongly prognosticates future adverse cardiovascular events, it may not reflect events that may result from plaques that are not yet calcified. Second, radiation exposure for CAC is low but non-negligible and must be considered carefully. The typical effective doses administered for CAC scanning are 1 mSv by electron beam CT and 3 mSv by multidetector row CT. 8) Given these doses, continuous efforts have been made to reduce the amount of radiation dosages without jeopardizing the assessment of CAC score by techniques such as lower tube voltage and current.
Further, a zero CAC score has been contended by some to allow stratification of individuals whose risk is sufficiently low that pharmacological therapies could be avoided. For example, it has been estimated that current guidelines would recommend statins for the majority of the United States population over age 60. 9) To this end, Nasir et al. 10) evaluated within the MultiEthnic Study of Atherosclerosis (MESA) population the degree of risk reclassification for statin eligibility due to CAC. Of the patients who were recommended for high-intensity statins, 41% had CAC = 0 and had only 5.2 events over 1000 personyears, far below the 7.5% yearly event rate attributed to them using the pooled cohort equations. Similarly, Miedema et al. 11) assessed the potential of CAC score for guiding aspirin use for the primary prevention of CAD in MESA. Participants with CAC score ≥ 100 had favorable risk/benefit estimates from aspirin use, while individuals with a zero CAC score would likely experience more harm than benefit. Finally, Bittencourt et al. 12) evaluated the potential benefit of a polypill according to CAC score among the MESA participants. Individuals with a zero CAC score had a very low event rate with a high projected number needed to treat. These results suggest that avoidance of therapy in subjects with a zero CAC score could allow for significant reductions in the population considered for treatment and the number needed to treat for preventing CAD events, and could potentially improve safety and cost.
While current guidelines largely support CAC score in asymptomatic individuals, some investigators have maintained that CAC has a role as a potential gatekeeper to downstream procedures in symptomatic populations. Several studies provide insight regarding the incremental diagnostic and prognostic value of CAC score in symptomatic patients. 13) In a study examining the prevalence and severity of CAD in 10037 patients with chest pain, a zero CAC score showed a negative predictive value (NPV) of 96% and 99% according to 50% and 70% coronary stenosis, respectively.
13)
Patients undergoing lung cancer screening by thoracic nongated CT often demonstrate calcified coronary artery atherosclerosis and recently, the combined detection of CAD and lung cancer has been encouraged. 14) In particular, the use of a one-time CT scan for identifying both CAC and lung cancer may display numerous benefits, including lower overall radiation exposure. Importantly, while there is generally high correlation between CAC and low dose lung cancer CT screening tests, there are practical differences in image acquisition and radiation dose between CAC scanning and low dose CT for lung cancer screening that relate to tube voltage and current, and electrocardiography (ECG) gating. To date, no study has evaluated the prognostic utility of CAC and low dose lung cancer screening CT when performed as a single exam, although such clinical trials are currently being designed.
Coronary CT Angiography
CCTA is a non-invasive tool that can directly visualize the coronary anatomy with a reportedly high diagnostic accuracy, rendering it useful for anatomical assessment of CAD. Previous large prospective studies have reported that CCTA accurately identifies the presence and severity of obstructive CAD. For instance, the Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography (ACCURACY) trial was the first prospective multicenter trial to evaluate the diagnostic accuracy of CCTA in symptomatic patients without known CAD. 15) Among 230 patients who underwent both CCTA and invasive coronary angiography (ICA), CCTA demonstrated high accuracy for detection of obstructive CAD with very high NPV (99%) for diagnosing patients with ≥ 70% stenosis. The Coronary Artery Evaluation Using 64-Row Multidetector Computed Tomography Angiography (CORE 64) study is a multicenter international trial using 64-slice CT detectors for identifying CAD in 291 patients with calcium scores ≤ 600.
16) The sensitivity, specificity, positive predictive value (PPV) and NPV of ≥ 50% stenosis in CCTA were 85%, 90%, 91%, and 83%, respectively. In comparison to the ACCURACY study, where those with severely obstructive (≥ 70%) coronary stenosis represented only 13.9 percent of the study sample, the CORE 64 study observed a higher prevalence of obstructive CAD (defined at a lower threshold at ≥ 50% stenosis) at 56%, resulted in an expectedly higher PPV at the cost of NPV when compared to the ACCURACY trial results. A third multicenter trial studying the diagnostic value of 64 CCTA by Meijboom et al. 17) documented the sensitivity, specificity, PPV and NPV for detecting patients with significant CAD (i.e., ≥ 50% lumen diameter reduction) was 99%, 64%, 86%, and 97%, respectively. This study reported a high sensitivity and NPV, similar to the ACCURACY trial. Impor-tantly, both the ACCURACY trial and the study by Meijboom et al. 17) enrolled only patients without known CAD, and suggests a very robust ability of CCTA to exclude obstructive CAD in this symptomatic population.
15)16)
The prognostic value of CCTA for clinical outcomes has been well established by the Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter (CON-FIRM) registry. 18) Among 23854 patients without known CAD, the incidence of mortality was significantly associated with obstructive CAD according to a per-patient, per-vessel, and persegment analysis. Further still, the absence of CAD by CCTA was associated with a favorable prognosis (e.g., annualized death rate = 0.28%). To this end, CCTA may prove useful for predicting future mortality outcomes, and may also serve an important role for effectively ruling out future cardiovascular events.
Direct head-to-head comparisons of CCTA to the more traditional used stress tests have been recently evaluated. Recently, The Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial aimed to compare clinical outcomes in symptomatic patients that required further evaluation to initial strategy of anatomical testing by use of CCTA or functional testing. 19) The adjusted hazard ratio for a CCTA strategy, as compared with a usual-care strategy of functional testing was 1.04 (95% confidence interval, 0.83 to 1.29), with adjustment for age, sex and several cardiovascular risk factors. In this study, there was a trend towards reduced rates of adverse clinical events at 12 months for individuals undergoing CCTA. To this end, the PROMISE trial indicates an initial strategy of CCTA performance is comparable to functional testing. Based upon this and similar data, current guidelines recommend the use of CCTA to symptomatic individuals, with a general focus on those considered low-to-intermediate risk. 20) Societal guidance documents also endorse the use of CCTA in patients with discordant ECG exercise and imaging results, such as those who continue to experience symptoms even with a normal ECG exercise test.
While some studies have suggested a clinical benefit of CCTA when screening asymptomatic populations, others have reported conflicting results. In general, the prognostic implications of screening for occult CAD in asymptomatic individuals with CCTA, rather than CAC, have not been addressed adequately due to their very low rate of hard events. 21)22) Cho et al. 23) explored risk stratification by CCTA in 7590 patients without chest pain syndrome. Although both CAC score and CCTA significantly improved the performance of standard risk factor prediction models (likelihood ratio p < 0.05 for all), the additional riskpredictive advantage by CCTA did not appear to be clinically meaningful in the general asymptomatic population. In select high risk patients, CCTA may offer benefit over CAC; among 400 asymptomatic diabetic individuals without known CAD, segment stenosis by CCTA was associated with increased major adverse cardiovascular events after adjusting for numerous CAD risk factors as well as CAC score.
22) Yet, the appropriate treatment of these individuals is still unknown. In the Screening for Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64 (FACTOR-64), a randomized controlled trial consisting of asymptomatic diabetic patients with relatively high cardiovascular risk, 24) 900 individuals were randomized to receive either screening with 64-slice CCTA or guideline-based optimal care. No differences in outcomes were observed between the CCTA and guideline-based strategy, although rates of adverse events were very low and thus may have lacked power to exclude a benefit to screening. Additional studies to improve our understanding of the utility of CCTA for risk stratification appear warranted. 20) CCTA enables assessment of atherosclerotic plaque volume and characteristics in a similar fashion to invasive intravascular ultrasound (IVUS). In a meta-analysis, CCTA proved to be highly accurate for determining plaque volume and area as compared with IVUS. 25) Recently, atherosclerotic plaque characteristics assessed by CCTA have been shown to be associated with ischemic lesions identified by invasive fractional flow reserve (FFR), whereby positive remodeling and low attenuation plaques were independently associated with myocardial ischemia (odd ratio: 5.30, p < 0.001, and odd ratio: 2.1, p = 0.038, respectively).
26) The latter findings suggest CCTA may be a useful adjunct for patient stratification and for improving specificity and PPV. Further, these atherosclerotic features identified by CCTA also provide predictive ability for future acute coronary syndromes and other adverse cardiovascular outcomes.
27)

Myocardial CTP
CCTA allows detection of anatomically obstructive coronary stenoses but, similar to anatomic evaluation by coronary angiography, cannot determine alone whether a stenosis is flow-limiting. In light of this, several prior studies have aimed to combine CCTA with established functional modalities, such as single photon emission CT (SPECT) or positron emission tomography myocardial perfusion imaging (MPI). 28) Although these approaches are feasible, they are generally burdensome to patients who are required to undergo at least two tests, while paying a penalty to cost and radiation exposure. In this regard, combined CCTA and CTP imaging may benefit the patient by enabling both morphologic and functional assessment of CAD into a single technique with high accuracy.
The majority of studies for CTP have employed a static single-energy approach, with comparable diagnostic performance compared to SPECT or ICA with SPECT. 29)30) Rochitte et al. 30) assessed the diagnostic performance of integrated CT angiography (CTA) and CTP for identification of individuals with flow-limiting CAD, as defined by ICA with a concomitant perfusion deficit on SPECT in the first multicenter study. The patient-based diagnostic accuracy of the combined CTA-CTP was 87% in all patients, and increased further to 90% and 93% when patients without prior myocardial infarction and known CAD were excluded, respectively. Subsequently, this study concluded that the integration of CTA and CTP could correctly identify individuals with obstructive CAD defined as ≥ 50% stenosis by ICA causing a perfusion defect by SPECT. Although recent advances in CT technology have allowed the assessment of CTP, there still exist significant limitations that constrain its widespread use in daily clinical practice. Artifacts from CTP are significant, and include beam hardening, misregistration, image noise and motion artifacts. Future improvements in CT technology might help to alleviate these artifactrelated problems. Others have appropriately contended that the additional cost and safety of additional contrast and radiation exposure should be continuously considered. Further, static CTP imaging is limited by the absence of quantitative techniques, but also by the acquisition of images for a single snap shot during the early arterial phase. 31) Dynamic myocardial CTP can overcome some flaws of static CTP and has emerged as a novel non-invasive imaging technique to evaluate reduced absolute myocardial blood flow. This technique has been demonstrated to have high diagnostic accuracy for the detection and exclusion of ischemic or infarcted myocardial segments. 32) Although the majority of studies have been limited by study sample size, the diagnostic performance of dynamic myocardial CTP has been to date investigated in comparison with SPECT and ICA, invasive FFR, or cardiac magnetic resonance imaging (MRI). [31] [32] [33] Ho et al. 33) evaluated the ability of stress dynamic myocardial CTP for detecting abnormal blood flow reserve and infarction in comparison to stress nuclear MPI. The results showed that sensitivity, specificity, PPV, and NPV were 0.83, 0.78, 0.79, and 0.82, respectively, when compared with SPECT MPI. While compared with ICA, the results of dynamic CTP were 0.95, 0.65, 0.78, and 0.79, respectively. Recently, Bamberg et al. 32) evaluated the use of dynamic CTP for the evaluation of myocardial ischemia in comparison to cardiac MRI. In that study, the diagnostic value of CT reported a sensitivity of 77.8%, specificity of 75.41%, NPV of 91.3%, and a modest PPV of 50.6%. Further, a higher diagnostic accuracy was observed for transmural perfusion defects and infarcted segments with a sensitivity of 87.8% and 85.3%, respectively. However, numerous potential limitations exist for dynamic CTP. Perhaps most importantly, the radiation dose of performing dynamic CTP is substantially higher compared to static CTP. Prior studies have reported average doses of ~20 mSv, equivalent to nearly 4-10 times CCTA doses. Also, the relatively long breath hold times and scan duration of 30 seconds that is necessary to complete the exam renders it difficult and uncomfortable to many patients. Furthermore, table movements may result in spatial misalignment. Thus, taking these points into consideration, additional studies along with further advances in CT technology are clearly needed to resolve these limitations.
FFRCT
Recently, application of computational fluid dynamics to typically acquired CCTA has allowed for a novel disruptive technology to calculate FFR from static CCTA data. FFR CT is utilized to assess the coronary anatomy without the need for additional radiation exposure, additional iodinated contrast, or administration of additional medications (Fig. 1) . To date, several prospective multicenter trials have evaluated the diagnostic performance of FFR CT compared to an invasive FFR reference standard. The Diagnosis of ISChemia-Causing Stenoses Obtained Via NoninvasivE FRactional FLOW Reserve (DIS-COVER-FLOW) study initially explored the diagnostic performance of FFR CT in 103 patients across 159 vessels. 34) Anatomical obstruction was defined as a CCTA with stenosis ≥ 50%, and ischemia was defined using FFR CT with FFR ≤ 0.80. On a per-vessel analysis, the accuracy, sensitivity, specificity, PPV, and NPV were 84.3%, 87.9%, 82.2%, 73.9%, and 92.2%, respectively. Using receiver operating characteristic curve analysis, the area under the curve (AUC) was 0.80 for FFR CT , which was significantly higher than the AUC based on CCTA (e.g., 0.75, p < 0.001). A follow-up study-the Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO) study-consisted of a larger population including 252 patients representing 407 vessels. 35) Of these patients, 137 (54.4%) had an abnormal FFR determined by invasive FFR. On a per-patient basis, diagnostic accuracy, sensitivity, specificity, PPV, and NPV of FFR CT plus CCTA were 73%, 90%, 54%, 67%, and 84%, respectively. Interestingly, diagnostic accuracy of FFR CT in patients with lesions of intermediate stenosis (i.e., 30% to 70% stenosis) was significantly higher sensitivity than CCTA only (82% versus 37%), without a change in specificity. Recently, the Analysis of Coronary Blood Flow Using CT Angiography: Next Steps (NXT) study also demonstrated high diagnostic performance of FFR CT . 36) Diagnostic accuracy, sensitivity, specificity, PPV, and NPV of FFR CT were 81%, 86%, 89%, 65%, and 93%, respectively. Compared with CCTA, FFR CT showed a significant reduction in the rate of false positives, particularly among those with lesions of intermediate stenosis (PPV: 63% versus 37%, p < 0.001). These prospective multicenter studies underscore the robustness of FFR CT to accurately pinpoint specific coronary lesions that cause ischemia, and extend the diagnostic paradigm beyond anatomically obstructive stenoses to lesion-specific ischemia.
Beyond improved diagnostic accuracy, FFR CT may also prove useful for guiding clinical decision-making. Using FFR CT to select patients for ICA and percutaneous coronary intervention (PCI) may lower health-related costs by 30% and may reduce the overall number of adverse cardiovascular events by 12% when compared to ICA or visual guidance for PCI. 37) Recently, the Prospective LongitudinAl Trial of FFR CT : Outcome and resource iMpacts study (PLATFORM) trial evaluated the utility of FFR CT to improve patient selection for ICA among 584 patients with new onset chest pain. Patients who were randomized to FFR CT had cancellation of ICA in 61% of all pa-tients, with normal ICA in only 12%, as compared to 73% of those randomized to usual care. 38) One potentially intriguing application of FFR CT is its use to perform "virtual stenting" by computational modeling of coronary flow after virtual modification. Indeed, Kim et al. 39) reported that there are a positive correlation between FFR CT and invasive FFR before and after stenting, with an overall accuracy of 96%. According to the latter study, treatment planning using FFR CT and 'virtual stenting' method can help to predict the therapeutic benefit of coronary revascularization prior to invasive coronary angiogram.
Novel Applications in Cardiac CT
Dual-energy CT
Recent developments in CT technology include dual-energy CT (DECT), a technique that allows for simultaneous or near- 
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simultaneous imaging with two energy spectra. By exploiting the use of two photon energy levels, DECT creates a noticeable difference between 2 materials with regard to their energy-specific attenuation profile. In this way, DECT can provide beneficial information regarding tissue composition by using differences in energy-dependent attenuation of different tissues, which primarily is the distinguishing feature of DECT compared with single energy CT (SECT). 40) To date, there are four methods of DECT that are practically available in the clinical setting that include: a dual-source dual-energy scanner (using two CT tubes and detectors), a single-source dual-energy scanner with fast kilovoltage switching (using a single CT tube and detector), a single-source dual-energy scanner with dual detector layers (using a single CT tube and 2 detector layers), and switching of energy levels between gantry rotations (Fig. 2) .
Several studies have demonstrated the diagnostic accuracy of DECT performed during rest or during a stress protocol in comparison to other modalities such as SPECT, ICA, or cardiac MRI.
41)42) Ruzsics et al. 41) assessed the diagnostic performance of MPI at rest by using DECT among 36 patients compared with SPECT. The sensitivity and specificity values were 92%, 93%, respectively, with an accuracy of 93% for detecting a perfusion defect on SPECT. Most recently, Kim et al. 42) evaluated the diagnostic value of adenosine-stress DECT using a secondgeneration (128-slice) dual-source CT (DSCT) for detecting myocardial perfusion defects compared with stress perfusion cardiac MRI in 50 patients. This study demonstrated a sensitivity and specificity of 77% and 94%, respectively, and the correlation between DECT perfusion and cardiac MRI was significantly positive (r = 0.602; p < 0.001).
Moreover, the DECT for ischemia determination compared to "gold standard" non-invasive and invasive techniques (DE-CIDE-Gold) trial was developed as a diagnostic performance study for testing rest-stress DECT angiography with perfusion. 43) The primary purpose of this study is to evaluate the diagnostic accuracy of dual-energy CCTA combined with dual-energy CTP for assessing the hemodynamic significance of CAD non-invasively, using FFR as a reference standard. The DECIDEGold trial will help determine the diagnostic performance of dual-energy CTP for the identification and exclusion of hemodynamically significant coronary artery stenosis.
Prior invasive and pathological studies have identified sev- eral high-risk anatomic plaque characteristics fundamental to the pathogenesis of sudden cardiac death as well as acute coronary syndromes. 27) These plaque features include plaque burden, thin-cap fibroatheroma, positive arterial remodeling, inflammatory infiltration, necrotic core, intraplaque hemorrhage, and spotty calcifications. 44) Several studies using conventional SECT have determined the classification of coronary artery plaques based upon attenuation values measured by HU, and have demonstrated substantial overlap in HU between fibrousrich and lipid-rich components. 45) Given that DECT images are acquired at two energy levels of photons, it has been considered that DECT may overcome these limitations. In a prospective study with tissue validation, Obaid et al. 46) observed that DECT improves the differentiation of necrotic core and fibrous plaque in ex vivo postmortem arteries (i.e., sensitivity of 64%; specificity of 98% vs. sensitivity of 50%; specificity of 94%) in comparison with SECT. However, for in vivo analysis, the sensitivity to detect necrotic core when using DECT was lower than SECT (39% vs. 45%).
DECT has also been evaluated for its ability to lower overall contrast requirements, Raju et al. 47) assessed the image quality and feasibility of a protocol with a reduced volume of iodinated contrast utilizing DECT angiography compared with a standard single-energy CCTA protocol. Although DECT angiography showed slightly inferior image quality, the signal-to-noise ratio and contrast-to-noise were comparable with the control group, with > 50% reduction in iodine dose. In this study, no differences were observed for overall radiation dose between SECT and DECT, with 2.31 ± 1.18 mSv for SECT and 2.23 ± 0.65 mSv for DECT, respectively.
Though DECT has recently seen a rapid progression in the field of cardiac CT, given the incipient stage for DECT, further studies are clearly required to validate its utility in clinical practice. By extension, the cost-effectiveness and clinical effectiveness based upon additional radiation exposure also warrants further consideration.
Strategies to enhance image quality
While CCTA has been well established as a highly accurate method for CAD detection and exclusion, several factors may limit the overall performance of CCTA, including relative tachycardias, arrhythmias, and/or high CAC levels. Thus these factors should be carefully considered prior to imaging procedures, given the effect they might impose on image quality and diagnostic accuracy, both of which are closely associated with spatial resolution and temporal resolution.
High-definition CT and iterative reconstruction
A newly introduced high definition CT (HDCT) scanner offers considerably improved in-plane spatial resolution to 0.23 mm, which is usually implemented with adaptive statistical iterative reconstruction to compensate for increased noise developed due to the higher spatial resolution of HDCT. Pontone et al. 48) compared the image quality, diagnostic value, diagnostic accuracy, and radiation exposure of HDCT compared with standard definition CT (SDCT). HDCT demonstrated a higher image quality score (3.7 vs. 3.4, p < 0.001) and better overall diagnostic value (97% vs. 92%, p < 0.002) in calcified lesions. Moreover, the specificity, PPV, and accuracy were higher in the HDCT group compared with the SDCT group (e.g., 98%, 91%, and 99% vs. 95%, 80%, and 95%, respectively; p < 0.001).
High-pitch CT
Pitch in cardiac CT is defined as the ratio of table travel per gantry rotation to the X-ray beam. In currently used spiral or helical CT, pitch is associated with radiation dose and noise. A pitch value > 1 indicates gaps between radiation beams and reduced radiation exposure at the expense of providing a lower resolution, while a pitch < 1 implies overlapping of X-ray beam with a concomitant increase in radiation exposure. 49) In singlesource CT, pitch is primarily limited to < 1.5 for guaranteeing gapless imaging. 50) Notably, DSCT that uses two detectors and two X-ray tubes arranged at a 90° angle has enabled higher pitch value, which allows for a reduced radiation dose. Additionally, only one-quarter rotation is necessary to acquire one image because of the unique geometry of the DSCT device. As such, image gaps in the trajectory of the first detector as a result of rapid table motion are covered by the second detector. With this technique, the entire heart can be scanned during one cardiac cycle. Several previous studies have shown that a high pitch mode can effectively reduce radiation exposure (1.0 ± 0.3 mSv), albeit these studies were restricted to patients with regular or low heart rate (HR) below 65 beats/min. 50) More recently, a third generation DSCT with high-pitch 192-slice CT can be performed at HR values up to 75 beats/min.
320-detector row CT
With advances in CT technology, 256-to-320 detector row CT have become available. These techniques have several advantages, including whole heart coverage resulting in contrast homogeneity and diminution of misregistration artifacts. Wong et al. 51) compared the image quality of a second generation 320-detector row CT in patients with elevated HR compared with first generation 320-detector row CT. Compared with the first generation CT scanner, the second generation CT scanner was superior for better image quality (3.94 ± 0.6 vs. 3.45 ± 0.8, p = 0.001) and required a lower radiation dose (2.8 mSv vs. 4.3 mSv, p = 0.009) in individuals with a HR ≥ 65 beats/min.
Motion correction algorithm
Motion of the coronary arteries is the most common factor that restricts accurate interpretation of CCTA. Particularly, motion artifacts can become aggravated due to a high HR or irregular rhythms during the scanning process, which may significantly mitigate the diagnostic accuracy of CCTA. To date, various efforts to reduce motion artifacts in patients with high HR have been performed, such as the use of HR lowering medications, high-pitch CT, DSCT, and 320-detector row CT. More recently, a novel vendor-specific intra-cycle motion correction algorithm (MCA) (GE Healthcare, Waukasha, WI, USA) has been developed to control motion artifacts. 52) This technique integrates image information from adjacent cardiac phases within a single cardiac cycle to characterize and compensate for coronary artery motion. Leipsic et al. 52) reported the diagnostic accuracy and effect on image quality after implementing MCA were improved in participants who underwent CCTA without HR controlling medications. Andreini et al. 53) assessed the diagnostic performance of MCA in conjunction with low-dose prospective ECG-triggering CCTA in patients with a pre-scanning HR > 70 beats/min or HR variability during scanning. Importantly, this study appeared to exclude individuals who initially presented with a very high HR and who were without HR-lowering therapy. In this regard, we await the findings from the Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY (VICTORY) trial, a multicenter international study that will further elaborate as to whether MCA enhances the diagnostic value among persons undergoing CCTA who receive HR lowering medications.
54)
Conclusion
In the recent past, cardiac CT has emerged as an extremely reliable tool for detection of CAD, with disruptive technologies such as FFR CT allowing for combined anatomic and physiologic assessment. In this review, we have provided a description of the benefits and disadvantages of several CCTA applications, having considered anatomic and physiologic assessment, as well as newer CT technologies (Table 1) . Further, we have reviewed novel methods for improvement of image quality and radiation dose (Table 2) . Continuing and future studies will help to define the clinical role of cardiac CT in the prevention and care of patients with cardiovascular disease.
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